COMP <GO>
PACS vs ABBV // PIOTROSKI F-SCORE QUALITY
PACS Group Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PACS 5
— ABBV 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: PACS
LAST: $47.81 (-3.76%) • MKT CAP: $7.87B
piotroski-score
9/9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PACS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PACS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.60% | 29.00% | -4.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.5x | 33.3x | -17.80 | PACS | /valuation <GO> |
| Free Cash Flow Yield | 2.11% | 3.47% | -1.36 | ABBV | /fcf-yield <GO> |
| Operating Margin | 5.90% | 24.60% | -18.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 3.60% | 6.90% | -3.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 29.40% | 8.60% | +20.80 | PACS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 5.33 | -3.09 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 7/9 | +2.00 | PACS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | PACS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.6 | 72.8 | -15.13 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.5x | 113.1x | -78.60 | PACS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.87B | $513.86B | -$505.99B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PACS REV | ABBV REV | PACS GROSS % | ABBV GROSS % | PACS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.29B | $61.16B | 44.0% | 70.2% | $166.3M | $17.82B |
| FY 2024 | $4.09B | $56.33B | 44.0% | 70.0% | $183.4M | $17.83B |
| FY 2023 | $3.11B | $54.32B | 44.0% | 44.0% | -$76.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PACS // BETA 0.95
ABBV // BETA 1.15